Employees
~1000
Stage
Commercial
Modalities
Medical devices

Urotronic General Information

Optilume drug-coated balloon technology received FDA approval and CE mark for treating urethral strictures and BPH. Clinical trials showed 94% clinical success rate at 30 days with no major adverse events.

Contact Information

Website
Primary Industry
Medical Devices
Corporate Office

Drug Pipeline

Optilume
Commercial
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Urotronic's pipeline data

Book a demo

Key Partnerships

Laborie Medical Technologies

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Urotronic Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Urotronic's complete valuation and funding history, request access »